Mesoblast (ASX:MSB): RYONCIL Commercial Launch and Cell Therapy Expansion Under Spotlight

Aditi Sarkar

14 August 2026 12:27 PM AEST

Mesoblast (ASX:MSB): RYONCIL Commercial Launch and Cell Therapy Expansion Under Spotlight

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast (ASX:MSB) generated US$115 million in RYONCIL net Revenue during its first full year of US commercial sales.
RYONCIL revenue reached US$36 million in Q4'FY26 as commercial rollout continued across paediatric transplant centres.
The company is progressing adult graft-versus-host disease and additional rare disease development programs.
Cash generation, Manufacturing execution and reimbursement remain key factors for future growth.

Mesoblast (ASX:MSB) has completed its first full year of commercial sales for RYONCIL, marking a transition from a development-stage biotechnology company towards a commercial cell therapy business.

The company’s FY26 results highlighted revenue generation from its first approved product, continued clinical expansion opportunities and progress towards broader applications of its cell therapy platform.

However, long-term success remains dependent on commercial scaling, reimbursement, manufacturing execution and additional regulatory approvals.

What Happened?

RYONCIL (remestemcel-L) received approval from the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.

It is the first mesenchymal stromal cell therapy to receive full FDA approval in the United States.

For the June 2026 quarter, Mesoblast reported RYONCIL net revenue of US$36 million.

For FY26, the company recorded US$115 million in RYONCIL net revenue, representing the first full year of commercial sales.

The product is currently being supplied to US transplant centres, with commercial activity focused on paediatric patients.

Why It Matters

RYONCIL represents an important milestone for Mesoblast because it demonstrates commercialisation of its allogeneic cell therapy platform.

The company spent years developing its technology while navigating regulatory and funding challenges. Commercial revenue from RYONCIL provides evidence that the manufacturing platform can support an approved therapy.

The paediatric SR-aGvHD indication provides an initial market entry point, while Mesoblast is targeting larger opportunities through additional indications.

The company is developing the adult SR-aGvHD market, which it estimates is approximately three times larger than the paediatric opportunity.

The Numbers

Mesoblast reported RYONCIL net revenue of US$115 million for FY26, including US$66.5 million generated during the second half.

Q4'FY26 RYONCIL revenue was US$36 million, compared with US$30.3 million in Q3'FY26.

Net operating cash spend for FY26 was US$43.8 million, including US$13.4 million in the second half.

The company ended FY26 with US$103 million in cash as at 30 June 2026 and drew US$50 million from an available financing Facility during the period.

Mesoblast reports product revenue in US dollars because RYONCIL sales are generated in the United States.

The company did not disclose gross margin, pricing details or payer coverage information in the results update.

The Bigger Picture

Beyond paediatric SR-aGvHD, Mesoblast is expanding RYONCIL development into adult patients with the same condition.

The company has commenced a registration trial in adult SR-aGvHD and expects to activate up to 40 US clinical sites.

Mesoblast is also developing other cell therapy applications.

The company has received FDA clearance to proceed with a registrational trial in Duchenne muscular dystrophy in children aged five to nine.

Its rexlemestrocel-L program continues in a Phase 3 chronic low back pain trial, while additional regulatory pathways are being explored for heart-failure-related gastrointestinal bleeding.

The company has also licensed CAR-MSC technology for inflammatory and autoimmune applications.

The Bull Case

The positive case for Mesoblast (ASX:MSB) is based on converting RYONCIL from an approved therapy into a broader commercial franchise.

The first year of sales provides an initial revenue base, while expansion into adult SR-aGvHD could increase the addressable market.

Additional approved indications could allow Mesoblast to Leverage its existing manufacturing platform across multiple therapies.

Reducing cash burn through product revenue would also improve financial flexibility as the company advances further clinical programs.

Risks Investors Should Understand

Mesoblast (ASX:MSB)’s Business faces risks including manufacturing complexity, reimbursement uncertainty, clinical trial outcomes and funding requirements.

Cell therapies require specialised manufacturing processes, and maintaining product quality while increasing production volumes can be challenging.

Commercial success depends on US payer coverage and sustained Demand for a high-value therapy.

The company continues to carry Debt and has used financing facilities, meaning slower-than-expected revenue growth could increase funding pressure.

Additional programs including adult SR-aGvHD, Duchenne muscular dystrophy and cardiovascular applications remain subject to clinical and regulatory risks.

What Comes Next?

The key upcoming milestones include continued RYONCIL commercial expansion, progress in the adult SR-aGvHD registration trial and further clinical developments across the pipeline.

Investors will monitor sales growth, manufacturing performance, reimbursement progress and changes in operating cash requirements.

Additional regulatory approvals would provide opportunities to expand use of Mesoblast’s cell therapy platform.

Conclusion

Mesoblast (ASX:MSB) has reached an important commercial milestone with US$115 million in first-year RYONCIL revenue, demonstrating progress from clinical development into product sales.

The launch provides a foundation for future growth, supported by potential expansion into adult SR-aGvHD and other therapeutic areas.

However, the company’s longer-term performance will depend on maintaining commercial growth, managing manufacturing complexity, securing reimbursement and successfully progressing additional clinical programs.

FAQs

Q: What is RYONCIL?

A:RYONCIL is Mesoblast’s approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children.

Q: How much revenue did RYONCIL generate in FY26?

A:RYONCIL generated US$115 million in net revenue during FY26.

Q: What other conditions is Mesoblast targeting?

A:Mesoblast is developing therapies for adult SR-aGvHD, Duchenne muscular dystrophy, chronic low back pain and other conditions.

Q: What was Mesoblast’s cash position?

A:Mesoblast reported US$103 million in cash as at 30 June 2026.

Q: What are the key risks for Mesoblast?

A:Key risks include manufacturing execution, reimbursement, clinical trials and future funding requirements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.